TherapeuticsMD (NASDAQ:TXMD) Issues Quarterly Earnings Results

TherapeuticsMD (NASDAQ:TXMD) released its quarterly earnings results on Wednesday. The company reported $0.01 earnings per share for the quarter, FiscalAI reports. TherapeuticsMD had a negative net margin of 17.94% and a negative return on equity of 2.01%. The company had revenue of $0.78 million during the quarter.

TherapeuticsMD Stock Down 3.3%

Shares of TherapeuticsMD stock traded down $0.06 during trading on Thursday, hitting $1.63. 146,288 shares of the stock traded hands, compared to its average volume of 230,782. The stock has a market cap of $18.81 million, a price-to-earnings ratio of -27.08 and a beta of 0.53. The firm’s fifty day moving average is $1.15 and its 200-day moving average is $1.19. TherapeuticsMD has a 52 week low of $0.70 and a 52 week high of $2.44.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of TherapeuticsMD in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.